Follistatin Research

Amthor H, et al.

The foundational study establishing the direct molecular interaction between follistatin and myostatin — the key biological relationship that makes follistatin relevant to muscle growth research. The researchers demonstrated that follistatin binds myostatin with extremely high affinity and physically blocks it from executing its muscle-suppressing function. When chick limb buds were treated with myostatin alone, expression of the myogenic genes Pax-3 and MyoD was severely reduced — but when follistatin was added alongside myostatin, this inhibition was completely blocked. This established follistatin as myostatin’s natural antagonist and the scientific foundation for all subsequent FS344 research.

Haidet AM, Rizo L, Handy C, et al.

A landmark study showing that a single intramuscular injection of AAV1-FS344 produced sustained increases in muscle mass and strength for over two years in both normal and dystrophic mice — including when treatment was started in aged animals. FS344 outperformed other myostatin inhibitors (GASP-1, FLRG) in terms of both muscle size and functional strength improvement. Crucially the study found no adverse effects on cardiac pathology or reproductive capacity in male or female treated animals — directly addressing the primary safety concern (FSH suppression) that had limited earlier follistatin research. This paper was the foundation for the first human clinical trial.

Rodino-Klapac LR, Haidet AM, Kota J, et al.

A comprehensive review establishing the scientific rationale for FS344 as a muscle disease therapeutic. The paper explains why the FS344 isoform specifically was selected for clinical development — its 10-fold lower affinity for activin compared to FS288 means it is far less likely to suppress FSH and interfere with reproductive function, the primary safety concern with follistatin. The review documents that AAV1-FS344 produced grip strength improvements in treated mice for over two years, and that muscle mass was increased across all treated animals. This paper set the stage for the first human clinical trial.

Gilson H, Schakman O, Kalista S, et al.

This study revealed that follistatin’s muscle-building effects operate through two distinct mechanisms — myostatin inhibition AND activin inhibition — and that satellite cells (muscle stem cells) play a critical role. FS overexpression increased muscle weight by 37% in normal animals but only 20% in irradiated animals (which lacked functional satellite cells), confirming that satellite cell proliferation drives a significant portion of the hypertrophic effect. Strikingly, FS produced equal muscle hypertrophy in both normal mice AND myostatin knockout mice — proving that follistatin’s muscle growth effects extend well beyond simply blocking myostatin, implicating activin and other TGF-β family members as additional targets.

Mendell JR, Sahenk Z, Malik V, et al.

The first human clinical trial of follistatin gene therapy — a landmark study delivering FS344 via intramuscular injection to patients with Becker muscular dystrophy. Six patients received bilateral quadriceps injections and were followed for safety and efficacy. The trial demonstrated that FS344 gene delivery was safe and well tolerated in humans, with no adverse reproductive effects or organ toxicity. Functional improvements in ambulation (walking ability) were observed in treated patients. This study represents the bridge between decades of animal research and human clinical application of follistatin — establishing its safety profile in humans for the first time.